ReviewMolecular diversity2026
Managing Malassezia species and related infections: new insights into recent natural and synthetic antifungal compounds and their mechanism of action.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malassezia spp. are lipophilic yeasts that colonize human and animal skin, being implicated in several dermatological and systemic disorders, including seborrheic dermatitis, pityriasis versicolor, and opportunistic fungemia in immunocompromised individuals. The increasing diffusion of resistant strains and the limited efficacy of conventional azole-based antifungal therapies have prompted the search for alternative treatment strategies. This review explores recent approaches to fighting Malassezia, focusing on both natural and synthetic compounds targeting key molecular pathways. Among the most innovative approaches are Malassezia carbonic anhydrases, essential enzymes involved in pH regulation and cellular metabolism, which represent promising and selective antifungal targets. The antifungal potential of plant-derived extracts rich in polyphenols, terpenoids, and flavonoids is also discussed, highlighting their ability to interfere with yeast growth and adhesion. Silver nanoparticles are examined as synergistic agents due to their antimicrobial properties and potential as carriers for natural bioactive compounds. Additional perspectives include the use of probiotics/postbiotics to restore skin microbiota balance, enzymes such as chitinase and chitosanase, and the inhibition of lipases, key enzymes in Malassezia lipid metabolism. Finally, the growing interest in antimicrobial peptides, both natural and synthetic, opens new avenues for targeted topical formulations. Overall, the integration of natural and synthetic approaches, supported by a deeper understanding of Malassezia's molecular mechanisms, may promote the development of more effective and safer multifactorial therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.